One codebase. Eight domains. 2,050+ validated equations. Every result from a single unmodified execution — no iterative tuning, no domain-specific engineering.
A team that owns both the technical build and the operational path to market. No academic distance between the code and the customer.
Built the core engine and led validation across all eight domains. Responsible for technical vision, product architecture, and every published result to date.
Leads business operations, financial strategy, and go-to-market execution. Structures partnerships and builds the operational foundation to scale.
We don't lead with projections. We lead with what's already shipping.
A stack of moats, not a single advantage. Each layer compounds with the next.
Provisional patent on the autonomous residual discovery engine and cross-domain equation validation framework. A competitor cannot legally re-implement the core innovation.
Baseball, healthcare, real estate, CRE, retail, transportation, oil & gas, and water systems. A competitor entering one vertical starts from scratch. We're already validated across eight from a single codebase.
Every new domain strengthens universal law discovery. Every universal law strengthens every client's Elijah. The more domains connected, the wider the moat — and the harder it is for a new entrant to catch up.
Unlike ML models that require retraining as distributions shift, validated mathematical equations are permanent. The equation library only grows — and brings clients with it. Retention is structural.
Black-box models cannot explain why. Elijah produces readable equations, sensitivity matrices, and feedback loops that domain experts can inspect, challenge, and trust. This is the only category regulators can actually sign off on.
The bottleneck in regulated industries isn't AI capability — it's trust, auditability, and interpretability. That's exactly what we sell.
AI healthcare market by 2034. Growing at 36.8% CAGR. The bottleneck is interpretability — not capability.
of healthcare leaders say their organizations cannot keep pace with AI adoption requirements.
of AI-discovered biomarker candidates ever reach clinical validation. The gap is interpretability.
The technology is built. Eight domains validated. Patent filed. A live pilot is already generating equations. This round funds commercial deployment, the first paying healthcare partner, and expansion into financial services. We're selective — we're looking for investors who will still be excited about equation intelligence five years from now.
Current round. Open to strategic and institutional investors.
Core discovery loop and cross-domain equation validation.
Proof of concept complete. Not a thesis — an infrastructure.
Questions, due diligence, or a conversation about where this fits in the stack.
michael.lazzarotti@diginetics.co